Abiomed Inc (ABMD) 104.25 $ABMD
ABIOMED Has Returned 20.8% Since SmarTrend Recommendation (ABMD)
Comtex SmarTrend(R) - Tue Jun 14, 1:40PM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on March 7th, 2016 at $84.30. In approximately 3 months, ABIOMED has returned 20.79% as of today's recent price of $101.83.
ABMD: 104.25 (+2.55)
How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
PR Newswire - Wed Jun 08, 7:55AM CDT
Increasing demands for new developments are driving up growth in the Medical Appliances and Equipment space, one of the biggest industries in the U.S. Healthcare sector. ActiveWallSt.com has lined the following stocks for investors' assessment: Edwards Lifesciences Corp. (NYSE: EW), Stryker Corp. (NYSE: SYK), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). Access these stocks complimentary alerts at:
ABMD: 104.25 (+2.55), EW: 99.08 (+1.04), ARAY: 5.26 (+0.13), SYK: 118.38 (+1.76)
Abiomed to Present at the William Blair 2016 Growth Stock Conference
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair 2016 Growth Stock Conference on Tuesday, June 14, 2016 at 9:30 a.m. CDT. The conference will be held at the Four Seasons Hotel in Chicago, IL.
ABMD: 104.25 (+2.55)
20.9% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)
Comtex SmarTrend(R) - Tue Jun 07, 12:59AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on March 7th, 2016 at $84.30. In approximately 3 months, ABIOMED has returned 20.87% as of today's recent price of $101.89.
ABMD: 104.25 (+2.55)
Abiomed to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Fri Jun 03, 8:00AM CDT
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT. The conference will be held at the Grand Hyatt New York in New York, NY.
ABMD: 104.25 (+2.55)
Masimo (MASI) Beats Q1 Earnings & Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:29AM CDT
Masimo Corp (MASI) reported earnings of 53 cents per share in the first quarter of 2016, which beat the Zacks Consensus Estimate by a dime.
ABMD: 104.25 (+2.55), IRMD: 21.48 (+0.14), MASI: 52.38 (+0.69), EW: 99.08 (+1.04)
Luminex (LMNX) Beats Q1 Earnings & Revenues, Guides Up
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:24AM CDT
Luminex Corporation (LMNX) reported first-quarter 2016 adjusted earnings of 27 cents per share, which comfortably surpassed the Zacks Consensus Estimate of 13 cents.
ABMD: 104.25 (+2.55), IRMD: 21.48 (+0.14), EW: 99.08 (+1.04), LMNX: 20.00 (+0.31)
Abiomed (ABMD) Down despite Q4 Earnings & Revenue Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:20AM CDT
Shares of Abiomed Inc. (ABMD) fell for the second consecutive day on May 4, after the release of the company's fourth-quarter 2016 results and fiscal 2017 guidance.
ABMD: 104.25 (+2.55), IRMD: 21.48 (+0.14), BAX: 45.96 (+1.02), EW: 99.08 (+1.04)
Abiomed beats Street 4Q forecasts
Automated Insights - Tue May 03, 6:59AM CDT
DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Tuesday reported fiscal fourth-quarter profit of $11 million.
ABMD: 104.25 (+2.55)
Abiomed Announces Q4 FY 2016 Revenue of $94.0 Million, Up 39% Over Prior Year
GlobeNewswire - Tue May 03, 6:01AM CDT
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2016 revenue of $94.0 million, an increase of 39% compared to revenue of $67.6 million for the same period of fiscal 2015. For fiscal year 2016, total revenue was $329.5 million, up 43% compared to revenue of $230.3 million in fiscal year 2015. This revenue exceeds the third quarter upgraded fiscal year guidance of $326 million.
ABMD: 104.25 (+2.55)
3 Scorching Hot Med-Tech Stocks In 2016
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 7:21AM CDT
Healthcare has taken some lumps in the past six months, but medical-device makers have been immune to the slump. While the Nasdaq Biotech ETF has tumbled 13.4% since last October, the iShares Medical Device ETF has climbed by 9.3%. That's a...
BSX: 22.97 (+0.31), ABMD: 104.25 (+2.55), EW: 99.08 (+1.04), IBB: 262.10 (+5.54), IHI: 135.39 (+2.35)
ABIOMED Shares Up 21.0% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Apr 27, 1:33AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on March 7th, 2016 at $84.30. In approximately 2 months, ABIOMED has returned 21.03% as of today's recent price of $102.03.
ABMD: 104.25 (+2.55)
How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 19, 8:43AM CDT
Image source: Abiomed. Over the past year, Abiomed stock has outperformed the iShares Global Healthcare ETF by a mile, and I'm sure Blackrock regrets not adding it to the ETF's holdings. Rapidly expanding sales, coupled with plenty of room...
ABMD: 104.25 (+2.55), STJ: 78.49 (+0.82), IXJ: 100.49 (+1.36)
4 Healthcare Stocks That Are Looking Cheap
Cory Renauer, The Motley Fool - Motley Fool - Sun Apr 17, 2:02PM CDT
Image source: Pixabay. After an indiscriminate beating of drug and device makers to begin the year, there are quite a few healthcare stocks on sale. I've pulled out a couple smaller companies poised for explosive growth, and a couple...
ABMD: 104.25 (+2.55), CLDX: 4.57 (+0.12), ABBV: 61.31 (+0.92)
Abiomed Fourth Quarter Fiscal 2016 Earnings and Conference Call Notification
Globe Newswire - Tue Apr 12, 7:01AM CDT
DANVERS, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, May 3, 2016, the Company will release financial results for the fourth quarter of fiscal 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.
ABMD: 104.25 (+2.55)
Abiomed Impella Devices Support 37,673 Patients, Enough to Fill Historic Fenway Park
GlobeNewswire - Tue Apr 12, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has supported 37,673 patients in the U.S. with its Impella(R) line of heart pumps, enough individuals to fill every seat in Fenway Park.
ABMD: 104.25 (+2.55)
Abiomed Impella(R) Therapy Receives FDA Approval for Cardiogenic Shock After Heart Attack or Heart Surgery
Globe Newswire - Thu Apr 07, 3:10PM CDT
Entire Family of Impella Left Side Heart Pumps FDA Approved To Enable Heart Recovery DANVERS, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella 2.5(TM), Impella CP(R), Impella 5.0(TM) and Impella LD(TM) heart pumps to provide treatment of ongoing cardiogenic shock. In this setting, the Impella heart pumps stabilize the patient's hemodynamics, unload the left ventricle, perfuse the end organs and allow for recovery of the native heart. This latest approval adds to the prior FDA indication of Impella 2.5 for high risk percutaneous coronary intervention (PCI), or Protected PCI(TM), received in March 2015.
ABMD: 104.25 (+2.55)
ABIOMED Has Returned 20.8% Since SmarTrend Recommendation (ABMD)
Comtex SmarTrend(R) - Tue Jun 14, 1:40PM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on March 7th, 2016 at $84.30. In approximately 3 months, ABIOMED has returned 20.79% as of today's recent price of $101.83.
ABMD: 104.25 (+2.55)
How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
PR Newswire - Wed Jun 08, 7:55AM CDT
Increasing demands for new developments are driving up growth in the Medical Appliances and Equipment space, one of the biggest industries in the U.S. Healthcare sector. ActiveWallSt.com has lined the following stocks for investors' assessment: Edwards Lifesciences Corp. (NYSE: EW), Stryker Corp. (NYSE: SYK), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). Access these stocks complimentary alerts at:
ABMD: 104.25 (+2.55), EW: 99.08 (+1.04), ARAY: 5.26 (+0.13), SYK: 118.38 (+1.76)
Abiomed to Present at the William Blair 2016 Growth Stock Conference
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair 2016 Growth Stock Conference on Tuesday, June 14, 2016 at 9:30 a.m. CDT. The conference will be held at the Four Seasons Hotel in Chicago, IL.
ABMD: 104.25 (+2.55)
20.9% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)
Comtex SmarTrend(R) - Tue Jun 07, 12:59AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on March 7th, 2016 at $84.30. In approximately 3 months, ABIOMED has returned 20.87% as of today's recent price of $101.89.
ABMD: 104.25 (+2.55)
Abiomed to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Fri Jun 03, 8:00AM CDT
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT. The conference will be held at the Grand Hyatt New York in New York, NY.
ABMD: 104.25 (+2.55)
Masimo (MASI) Beats Q1 Earnings & Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:29AM CDT
Masimo Corp (MASI) reported earnings of 53 cents per share in the first quarter of 2016, which beat the Zacks Consensus Estimate by a dime.
ABMD: 104.25 (+2.55), IRMD: 21.48 (+0.14), MASI: 52.38 (+0.69), EW: 99.08 (+1.04)
Luminex (LMNX) Beats Q1 Earnings & Revenues, Guides Up
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:24AM CDT
Luminex Corporation (LMNX) reported first-quarter 2016 adjusted earnings of 27 cents per share, which comfortably surpassed the Zacks Consensus Estimate of 13 cents.
ABMD: 104.25 (+2.55), IRMD: 21.48 (+0.14), EW: 99.08 (+1.04), LMNX: 20.00 (+0.31)
Abiomed (ABMD) Down despite Q4 Earnings & Revenue Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:20AM CDT
Shares of Abiomed Inc. (ABMD) fell for the second consecutive day on May 4, after the release of the company's fourth-quarter 2016 results and fiscal 2017 guidance.
ABMD: 104.25 (+2.55), IRMD: 21.48 (+0.14), BAX: 45.96 (+1.02), EW: 99.08 (+1.04)
Abiomed beats Street 4Q forecasts
Automated Insights - Tue May 03, 6:59AM CDT
DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Tuesday reported fiscal fourth-quarter profit of $11 million.
ABMD: 104.25 (+2.55)
Abiomed Announces Q4 FY 2016 Revenue of $94.0 Million, Up 39% Over Prior Year
GlobeNewswire - Tue May 03, 6:01AM CDT
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2016 revenue of $94.0 million, an increase of 39% compared to revenue of $67.6 million for the same period of fiscal 2015. For fiscal year 2016, total revenue was $329.5 million, up 43% compared to revenue of $230.3 million in fiscal year 2015. This revenue exceeds the third quarter upgraded fiscal year guidance of $326 million.
ABMD: 104.25 (+2.55)
3 Scorching Hot Med-Tech Stocks In 2016
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 7:21AM CDT
Healthcare has taken some lumps in the past six months, but medical-device makers have been immune to the slump. While the Nasdaq Biotech ETF has tumbled 13.4% since last October, the iShares Medical Device ETF has climbed by 9.3%. That's a...
BSX: 22.97 (+0.31), ABMD: 104.25 (+2.55), EW: 99.08 (+1.04), IBB: 262.10 (+5.54), IHI: 135.39 (+2.35)
ABIOMED Shares Up 21.0% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Apr 27, 1:33AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on March 7th, 2016 at $84.30. In approximately 2 months, ABIOMED has returned 21.03% as of today's recent price of $102.03.
ABMD: 104.25 (+2.55)
How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 19, 8:43AM CDT
Image source: Abiomed. Over the past year, Abiomed stock has outperformed the iShares Global Healthcare ETF by a mile, and I'm sure Blackrock regrets not adding it to the ETF's holdings. Rapidly expanding sales, coupled with plenty of room...
ABMD: 104.25 (+2.55), STJ: 78.49 (+0.82), IXJ: 100.49 (+1.36)
4 Healthcare Stocks That Are Looking Cheap
Cory Renauer, The Motley Fool - Motley Fool - Sun Apr 17, 2:02PM CDT
Image source: Pixabay. After an indiscriminate beating of drug and device makers to begin the year, there are quite a few healthcare stocks on sale. I've pulled out a couple smaller companies poised for explosive growth, and a couple...
ABMD: 104.25 (+2.55), CLDX: 4.57 (+0.12), ABBV: 61.31 (+0.92)
Abiomed Fourth Quarter Fiscal 2016 Earnings and Conference Call Notification
Globe Newswire - Tue Apr 12, 7:01AM CDT
DANVERS, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, May 3, 2016, the Company will release financial results for the fourth quarter of fiscal 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.
ABMD: 104.25 (+2.55)
Abiomed Impella Devices Support 37,673 Patients, Enough to Fill Historic Fenway Park
GlobeNewswire - Tue Apr 12, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has supported 37,673 patients in the U.S. with its Impella(R) line of heart pumps, enough individuals to fill every seat in Fenway Park.
ABMD: 104.25 (+2.55)
Abiomed Impella(R) Therapy Receives FDA Approval for Cardiogenic Shock After Heart Attack or Heart Surgery
Globe Newswire - Thu Apr 07, 3:10PM CDT
Entire Family of Impella Left Side Heart Pumps FDA Approved To Enable Heart Recovery DANVERS, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella 2.5(TM), Impella CP(R), Impella 5.0(TM) and Impella LD(TM) heart pumps to provide treatment of ongoing cardiogenic shock. In this setting, the Impella heart pumps stabilize the patient's hemodynamics, unload the left ventricle, perfuse the end organs and allow for recovery of the native heart. This latest approval adds to the prior FDA indication of Impella 2.5 for high risk percutaneous coronary intervention (PCI), or Protected PCI(TM), received in March 2015.
ABMD: 104.25 (+2.55)
